Best Genomics Companies in South Korea
The 132 best Genomics companies in South Korea in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Rznomics.
South Korea's Genomics sector has 132 companies on our radar, and the $294M in disclosed funding across them tells a story worth unpacking before you scroll the directory. Rznomics leads the pack at $49M raised, with Wellmarker Bio at $45M and Lemonex at $27M not far behind. No unicorns yet, but the funding distribution is uneven in the way that matters: a handful of bets are pulling away. The global market context backs the momentum, with genomics forecast to grow from roughly $24.3B toward $85.1B by 2030, a 16.37% CAGR driven by falling sequencing costs and the push toward personalized medicine.
So what's actually moving in South Korea right now? Machine learning drug discovery and pharmacogenomics are the themes attracting the most attention from active investors like IMM Investment, Korea Investment Holdings, and DSC Investment. Genomics is also surfacing in broader industrial conversations globally, including Mukesh Ambani's recent framing of it as a pillar of future growth alongside AI. I'd watch hereditary disease genomics closely this quarter. The capital is concentrating fast, and the companies ranked here reflect both total disclosed equity and recent funding momentum.
- Genomics Market Size to Grow by USD 18,244.34 million from 2022 to 202
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in South Korea
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Rznomics Developer of drugs for anti-cancer and refractory diseases based on RNA Platform technology 57Growth top 15%Patents top 28%Moat top 32%Innovation top 33% All 9 signals ▾Growthtop 15% Patentstop 28% Moattop 32% Innovationtop 33% Fundingtop 38% Talentbottom 49% Marketbottom 44% Globalbottom 42% Techbottom 22% Growth: Web rank 50,000,000 → 5,000,000 YoY Patents: 61 patents matched (strict assignee match) · 51 filings since 2022 vs 10 in 2017-21 rank vs industry peers · Fliar Intelligence Index 57/100 | $49M | 48 mo ago | 39 | 2017 | Seong-Wook Lee Founder & CEO | 61 patents Therapeutic circular RNA and trans‑splicing ribozyme platforms for gene‑editing and drug delivery | — |
| 2 | Wellmarker Bio Developer of biomarker-based therapeutics for the treatment of cancer | $45M | 83 mo ago | 58 | 2016 | Dong Hoon Co-Founder & Co-CEO | 85 patents Targeted antibody therapeutics and biomarkers for cancer and kinase inhibitor response | — |
| 3 | Lemonex Developer of drug delivery technology and biosensor technology | $27M | 62 mo ago | 9 | 2013 | Dal-Hee Min Co-Founder & CTO | 181 patents Nanocarrier-based drug and nucleic‑acid delivery systems for antiviral and cancer therapies | — |
| 4 | 3billion Provider of AI-driven clinical diagnostic testing platform for rare genetics disease 74Product top 19%Tech top 22%AI top 25%Patents top 26% All 12 signals ▾Producttop 19% Techtop 22% AItop 25% Patentstop 26% Talenttop 28% Innovationtop 32% Moattop 32% Fundingtop 34% Growthtop 35% Marketbottom 49% Globalbottom 43% Fin. healthbottom 36% Product: 3 distinct product lines · Company stage: Public Tech: 49 technologies across 5/8 capability areas · Cloud: Amazon Cloudfront, Amazon S3 rank vs industry peers · Fliar Intelligence Index 74/100 | $26M | 1 mo ago | 75 | 2016 | — | 59 patents AI-powered genomic variant analysis and clinical symptom similarity for precision medicine | 1 partnership |
| 5 | Pharmcadd Provider of CAAD based drug discovery platform | $22M | 62 mo ago | 35 | 2019 | Woo Wook Founder | 21 patents AI-based protein structure prediction and piperidine-derived drug discovery | — |
| 6 | Deargen Developer of AI-based drug discovery platform for rare and intractable diseases | $17M | 51 mo ago | 39 | 2016 | Gilsu Kang CEO | 72 patents AI-driven small‑molecule design and target interaction prediction for drug discovery | — |
| 7 | Geninus Developer of genomic-based disease prevention platform | $13M | 70 mo ago | 94 | 2018 | — | 39 patents Molecular diagnostics and immuno‑oncology biomarkers for cancer detection and therapy prediction | — |
| 8 | NGeneBio In vitro cancer diagnostic products | $13M | 90 mo ago | 124 | 2015 | Min-Sik Kim Co-CEO | 46 patents Genetic diagnostics and personalized therapeutics via nucleic‑acid amplification and microbiome analysis | — |
| 9 | G + FLAS Life Sciences Developing gene editing technologies for new drugs and plant-based biopharmaceuticals | $12M | 81 mo ago | 9 | 2014 | Sunghwa Choe CEO | 88 patents CRISPR-based gene therapies and plant‑derived biologics for targeted cancer treatment | — |
| 10 | Genacast Provider of liquid-biopsy-based cancer detection platform | $12M | 72 mo ago | 27 | 2016 | Seung Chan Baek CEO | — | — |
| 11 | Abion Therapeutics for cancer and auto-immune diseases. | $11M | 130 mo ago | 33 | 2007 | — | 229 patents Kinase inhibitor small molecules and interferon‑beta biologics for cancer and antiviral therapies | — |
| 12 | AIGEN Sciences AI-based drug discovery and designing tool for researchers 35AI top 30%Moat top 38%Funding top 42%Patents top 46% All 8 signals ▾AItop 30% Moattop 38% Fundingtop 42% Patentstop 46% Innovationtop 48% Talentbottom 49% Globalbottom 31% Marketbottom 25% AI: Classified as an AI company · Product described with: ai-based Moat: Editorial + unicorn rating 4/10 · IP moat: 7 patents rank vs industry peers · Fliar Intelligence Index 35/100 | $9M | 11 mo ago | 8 | 2021 | Jaewoo Kang CEO | 7 patents Patents concentrated in chemistry & materials | — |
| 13 | NewLacel Genetics Developer of adeno-associated virus gene therapy to treat neurodegenerative diseases | $9M | 91 mo ago | — | 2018 | — | — | — |
| 14 | ENCell Provider of services for stem cell research for drug development | $8M | 74 mo ago | 104 | 2018 | Jang wook CEO | 70 patents Patents concentrated in chemistry & materials | — |
| 15 | Apicell Therapeutics Developer of gene therapies for the treatment of immunological diseases | $7M | 47 mo ago | 25 | 2020 | Seng-Ho Jeon CEO | — | — |
| 16 | Panagene Provider of peptide nucleic acid products for diagnostic and therapeutic use | $5M | 114 mo ago | 71 | 2001 | Sung Kee Kim President & CEO | 170 patents Patents concentrated in chemistry & materials | 1 launch |
| 17 | Novomics Developer of a molecular diagnosis system for cancer treatment | $3M | 114 mo ago | 5 | 2010 | Huh Yongmin CEO | 36 patents AI-based gastric cancer imaging analysis and predictive biomarkers for therapy response | — |
| 18 | Genome & Company Developer of microbiome-based immuno-oncology drugs | $3M | 73 mo ago | 108 | 2015 | Jisoo Pae Co-Founder & CEO | 252 patents Patents concentrated in computing, sensing & instrumentation | — |
| 19 | Seegene Technologies Developer of molecular diagnostic kits to detect infectious and genetic diseases | $2M | 78 mo ago | — | 2000 | Jong Yoon Chun CEO | 1,257 patents Multiplex nucleic‑acid diagnostic assay design, automation, and data‑driven infectious disease testing | 1 launch · 1 award |
| 20 | ichrogene Provider of DNA data upload and analysis for genetic insights | $944K | 77 mo ago | — | 2017 | Youngah Shin Founder & CEO | 10 patents Pharmacogenomic risk prediction and personalized medicine platforms for type 2 diabetes | — |
Top 12 Genomics companies in South Korea
#1
Public · Seoul, Seoul · founded 2016 · 75 employees$25.7Mraised▾
Provider of AI-driven clinical diagnostic testing platform for rare genetics disease. It uses a combination of next-generation sequencing, and advanced machine learning and deep learning algorithms to analyze whole patient genomes for disease-causing mutations. The company is developing a single test that can detect more than 4000 rare genetic disorders.
- Apr 2026Series D$20.3M
- Mar 2021Series C$13M
- Oct 2019Series B$10M
- Jul 2018Series A$2.7M
#2
Series A · Seoul, Seoul · founded 2021 · 8 employees$8.8Mraised▾
AI-based drug discovery and designing tool for researchers. The company has developed a proprietary tool AIGEN Discovery that assists with the discovery and designing of new drugs. The system can be used for drug targeting, data analysis, novel compounds optimization, and more.
- Jul 2025Series A—
- Oct 2024Series A$8.8M
#3
Public · Yongin si, Gyeonggi do · founded 2017 · 39 employees$48.7Mraised▾
Developer of drugs for anti-cancer and refractory diseases based on RNA Platform technology. It has developed gene therapy products for the treatment of various cancers, degenerative diseases, hereditary diseases of liver cancer, and others. It's lead products RZ001that helps in treating cancer diseases, RZOO2, RZ003 helps in the treatment of Alzheimer's diseases.
- Jun 2022Series C$29.8M
- Sep 2019Series A$10M
#4
Series B · Seoul, Seoul · founded 2016 · 58 employees$45.2Mraised▾
Developer of biomarker-based therapeutics for the treatment of cancer. The company has a drug pipeline of small molecules (WM-S1), antibodies(WM-A1), and protein (WM-P1) therapies in the preclinical stage targeting various cancers including colon, breast, NSLC, liver, and prostate. WM-S1 is CRG targeted inhibitor and WM-A1 is an antibody targeting cancer immunotherapy-related genes (CMG).
- Jul 2019Series B$16M
- Nov 2018Series A$25M
- Apr 2018Seed$4.2M
#5
Series C · Seoul, Seoul · founded 2013 · 9 employees$27.5Mraised▾
Developer of drug delivery technology and biosensor technology. The DegradaBALLis a drug delivery technology for the development of gene therapy, cancer immunotherapy, antibody therapy, and synthetic drugs. The PANGO technology is the next-generation drug screening technology that allows the rapid screening of antiviral drugs from the drug candidate library.
- Apr 2021Series C$13.9M
- Dec 2018Series B$10.3M
- Mar 2018Series A$3.3M
#6
Series B · Seoul, Seoul · founded 2016 · 39 employees$17Mraised▾
Developer of AI-based drug discovery platform for rare and intractable diseases. The company's platform comprises genome data analysis, biomarker prediction, molecule selection, and optimization. It is used for discovering new disease targets for developing small molecule precision medicine.
- Feb 2022Series B$17M
#7
Series B · Busan, Busan · founded 2019 · 35 employees$22Mraised▾
Provider of CAAD based drug discovery platform. The Pharmulator platform uses AI, network theory, quantum calculation, and molecular dynamics that predict protein structure to design and synthesize new drug candidates. The company is developing drugs for NAOC, cancer, Alzheimers, and covid-19.
- Mar 2021Series B$15.5M
#8
Series A · Gimhae si, South Gyeongsang Province · founded 2020 · 25 employees$7.3Mraised▾
Developer of gene therapies for the treatment of immunological diseases. The company is developing a cell gene therapy based on mesenchymal stem cells (MSC) by using Affimer platform technology to develop therapies for incurable diseases such as autoimmune diseases and transplant rejection.
- Jul 2022Series A—
- Feb 2021Series A$7.3M
#9
Public · Seoul, Seoul · founded 2018 · 94 employees$13.3Mraised▾
Geninus is a developer of a genomic-based disease prevention platform. It has developed a CancerScan test that detects mutations by deep sequencing based on NGS of tumor DNA extracted from cancer tissue . It supports in mutation detection and related target anticancer drugs with clinical utility through genomic analysis of cancer tissues. It also offers diet service through microbial community analysis by using genetic analysis technology. It provides single cell analysis service that analyzes single cells in the cancer genome. It helps to analyze the characteristics of individual cells and their distribution, type, and condition by cell type. It also offers services like LiquidSCAN, HealthSCAN, cancer genome analysis, microbial community genome, and many more.
- Aug 2020Series B$13.3M
- Dec 2018Series A—
- Oct 2018Angel—
#10
Series B · Seoul, Seoul · founded 2016 · 27 employees$11.6Mraised▾
“The earlier you discover, the better you recover†GENECAST is biotechnology company specialized in cancer diagnosis using liquid biopsy. ADPS, our proprietary technology which has maximum detection sensitivity of 0.0001%, can recognize cancer mutation genes quickly and accurately among other conventional liquid biopsy technologies. FACE CANCER with ADPS
#11
Public · Seoul, Seoul · founded 2015 · 124 employees$12.9Mraised▾
NGeneBio is offering products for in vitro diagnostic of oncology. It offers breast cancer detection kit, NSC for solid tumor detection, hematological malignancy panel, along with bioinformatics analysis software, and a genetic test for the short tandem repeat. The product portfolio of the company includes next-generation sequencing (NGS)-based in vitro diagnostics (IVD) panel and clinical analysis software (SW) for applications in molecular diagnostics (MDx) and companion diagnostics (CDx). It can detect the mutation in BRCA genes.
- Dec 2018Series B$11M
- 2017Seed$1.9M
#12
Series C · Cheongju-si, Chungcheongbuk-do · founded 2014 · 9 employees$12Mraised▾
Developing gene editing technologies for new drugs and plant-based biopharmaceuticals. It focuses on CRISPR-CasN enzymes and CRISPR gene editing to create innovative solutions in healthcare and agriculture. The offerings include CRISPR genome editing, CRISPR services, and protein synthesis. They are developing new drugs, plant-based biopharmaceuticals, and novel crop varieties enriched with vitamins and nutrients. It utilizes platforms like Cancerase for cancer therapeutics and PDB for plant-based biopharmaceuticals. It also focus on Non-GMO editing using Glyco-engineering. It aims to deliver advancements through gene editing, impacting both the pharmaceutical and agricultural sectors with its technology.
- Aug 2019Series C$12M
- 2016Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in South Korea
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,344 South Korea-affiliated papers.
- Ministry of Education187
- Seoul National University134
- Yonsei University85
- Ministry of Agriculture72
- Korea University65
- Gene3→61
- Genome5→47
- Identification (biology)3→24
- CRISPR3→16
- Transcription factor1→13
- Gene2→43
- Cancer2→30
- microRNA1→9
- Cancer therapy1→6
- Disease1→26
- Diabetes mellitus1→5
Where bioinformatics is researched across South Korea
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing bioinformatics patents in South Korea
South Korea bioinformatics patent filing is cooling — 20 filings from 6 assignees (2016–2025), led by Korea Basic Science INST, Pharmcadd, Deargen; annual filings 2→1.
- Korea Basic Science INST10
- Pharmcadd7
- Deargen3
- Samsung3
- Istech2
- Gardner Steve1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.